文献速递肝病消化道肿瘤与早癌

美国慢性乙型肝炎相关肝细胞癌风险预测模型的比较性能

Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States.
PubMed 文献 · J Hepatol · 2021-09-23

该回顾性队列研究纳入3101例接受核苷(酸)类似物治疗的慢性乙型肝炎患者,比较10种HCC风险预测模型的区分度和校准度。中位随访4.5年,113例发生HCC,发病率0.75/100人年。RWS-HCC、APA-B、REAL-B和AASL-HCC的3年HCC风险AUC均>0.80,表现最佳;多数模型区分度良好,部分模型可识别3年内无HCC发生的低风险人群。

要点

  • RWS-HCC、APA-B、REAL-B和AASL-HCC对3年HCC风险的AUC均>0.80,区分度最佳。
  • PAGE-B、m-PAGE-B、AASL-HCC和REAL-B定义的低风险组在随访期间无HCC发生。
  • 多数模型区分度良好,但APA-B校准度较差。

核心结论

  • 在美国接受抗病毒治疗的HBV患者中,多数HCC风险预测模型区分度良好。
  • RWS-HCC、REAL-B和AASL-HCC表现最佳,部分模型可识别3年内无HCC发生的低风险组。

研究设计与样本

  • 回顾性队列研究,纳入2008年9月1日至2018年12月31日在130家退伍军人事务机构接受核苷(酸)类似物治疗的3101例HBV患者,其中32.2%有肝硬化。
  • 计算10种HCC风险预测模型(REACH-B、PAGE-B、m-PAGE-B、CU-HCC、HCC-RESCUE、CAMD、APA-B、REAL-B、AASL-HCC、RWS-HCC)的风险评分,评估区分度和校准度。
  • 中位随访4.5年,113例发生HCC,发病率为0.75/100人年。

主要发现

  • 3年HCC风险的AUC值最高为RWS-HCC、APA-B、REAL-B和AASL-HCC(均>0.80),其中APA-B、RWS-HCC、REAL-B纳入甲胎蛋白。
  • 其他模型AUC范围从PAGE-B的0.73到CAMD和HCC-RESCUE的0.79。
  • AUC>0.75的7个模型中,仅APA-B校准度较差。
  • 根据已发表截断值,10-20%的队列被归为低风险;PAGE-B、m-PAGE-B、AASL-HCC和REAL-B定义的低风险组在随访期间无HCC发生。

关键数值与推荐

  • 3年HCC风险AUC:RWS-HCC、APA-B、REAL-B、AASL-HCC均>0.80;PAGE-B为0.73;CAMD和HCC-RESCUE为0.79。
  • 10-20%的患者根据已发表截断值被归为低风险。
  • PAGE-B、m-PAGE-B、AASL-HCC和REAL-B定义的低风险组在3年研究期间无HCC发生。

临床怎么用

  • 在抗病毒治疗的HBV患者中,可考虑使用RWS-HCC、REAL-B或AASL-HCC等模型评估HCC风险以指导监测决策。
  • 部分模型(如PAGE-B、m-PAGE-B、AASL-HCC、REAL-B)识别的低风险患者或许可考虑免除HCC监测,但需进一步研究确认。

局限性

  • 研究为回顾性队列,结论需在前瞻性研究中验证。
  • 是否可安全地将低风险患者排除在HCC监测之外尚需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Guidelines recommend hepatocellular carcinoma (HCC) surveillance in patients with chronic HBV infection. Several HCC risk prediction models are available to guide surveillance decisions, but their comparative performance remains unclear. METHODS: Using a retrospective cohort of patients with HBV treated with nucleos(t)ide analogues at 130 Veterans Administration facilities between 9/1/2008 and 12/31/2018, we calculated risk scores from 10 HCC risk prediction models (REACH-B, PAGE-B, m-PAGE-B, CU-HCC, HCC-RESCUE, CAMD, APA-B, REAL-B, AASL-HCC, RWS-HCC). We estimated the models' discrimination and calibration. We calculated HCC incidence in risk categories defined by the reported cut-offs for all models. RESULTS: Of 3,101 patients with HBV (32.2% with cirrhosis), 47.0% were treated with entecavir, 40.6% tenofovir, and 12.4% received both. During a median follow-up of 4.5 years, 113 patients developed HCC at an incidence of 0.75/100 person-years. AUC values for 3-year HCC risk were the highest for RWS-HCC, APA-B, REAL-B, and AASL-HCC (all >0.80). Of these, 3 (APA-B, RWS-HCC, REAL-B) incorporated alpha-fetoprotein. AUC values for the other models ranged from 0.73 for PAGE-B to 0.79 for CAMD and HCC-RESCUE. Of the 7 models with AUC >0.75, only APA-B was poorly calibrated. In total, 10-20% of the cohort was deemed low-risk based on the published cut-offs. None of the patients in the low-risk groups defined by PAGE-B, m-PAGE-B, AASL-HCC, and REAL-B developed HCC during the study timeframe. CONCLUSION: In this national cohort of US-based patients with HBV on antiviral treatment, most models performed well in predicting HCC risk. A low-risk group, in which no cases of HCC occurred within a 3-year timeframe, was identified by several models (PAGE-B, m-PAGE-B, CAMD, AASL-HCC, REAL-B). Further studies are warranted to examine whether these patients could be excluded from HCC surveillance. LAY SUMMARY: Risk prediction models for hepatocellular carcinoma (HCC) in patients infected with hepatitis B virus (HBV) could guide HCC surveillance decisions. In this large cohort of US-based patients receiving treatment for HBV, most published models discriminated between those who did or did not develop HCC, although the RWS-HCC, REAL-B, and AASL-HCC performed the best. If confirmed in future studies, these models could help identify a low-risk subset of patients on antiviral treatment who could be excluded from HCC surveillance.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Kim HS, Yu X, Kramer J, et al. Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States. J Hepatol. 2021. PMID: 34563579. doi:10.1016/j.jhep.2021.09.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。